Clinical relevance of HCV antiviral drug resistance
Authors:
- 31 October 2012
- journal article
- review article
- Published by Elsevier in Current Opinion in Virology
- Vol. 2 (5) , 651-655
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (DFG)
- DFG Research Fellowship
This publication has 16 references indexed in Scilit:
- New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectivesGut, 2012
- Peptidomimetic Escape Mechanisms Arise via Genetic Diversity in the Ligand-Binding Site of the Hepatitis C Virus NS3/4A Serine ProteaseGastroenterology, 2012
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious VirusGastroenterology, 2011
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C VirusScience Translational Medicine, 2010
- Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus InfectionGastroenterology, 2010
- Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients†Hepatology, 2009
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsHepatology, 2008
- Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor TelaprevirGastroenterology, 2007